Neuroactive steroids: Mechanisms of action and neuropsychopharmacological properties

Psychoneuroendocrinology

Volumn 28, Issue 2, 2003, Pages 139-168

  Rupprecht, Rainer ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Anxiety; Depression; GABAA receptor; Ligand gated ion channels; Neuroactive steroids; Neurosteroids

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR; ALCOHOL; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; DEOXYCORTICOSTERONE; DRUG RECEPTOR; ESTRADIOL; GABAERGIC RECEPTOR AFFECTING AGENT; GLUTAMATE RECEPTOR; ION CHANNEL; MEMBRANE RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR; SEROTONIN; STEROID; STEROID HORMONE; TESTOSTERONE; TRANSCRIPTION FACTOR;

ANXIETY; ARTICLE; BINDING SITE; BRAIN FUNCTION; CHANNEL GATING; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; GENE CONTROL; GENE EXPRESSION; GENOMICS; HUMAN; IN VIVO STUDY; INTRACELLULAR SPACE; LOCOMOTION; MAJOR DEPRESSION; MENTAL DISEASE; METABOLITE; NONHUMAN; PANIC; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; STRUCTURE ACTIVITY RELATION;

EID: 0037293399     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(02)00064-1     Document Type: Article

References (145)

1. Akwa Y., Morfin R.F., Robel P., Baulieu E.E. Neurosteroid metabolism, 7 alpha-hydroxylation of dehydroepiandrosterone and pregnenolone by rat brain microsomes. Biochem. J. 288:1992;959-964.
2. Araneo B., Daynes R. Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury. Endocrinology. 136:1995;393-401.
3. Azuma T., Nagai Y., Saito T., Funauchi M., Matsubara T., Sakoda S. The effect of dehydroepiandrosterone sulfate administration to patients with multi-infarct dementia. J. Neurol. Sci. 162:1999;69-73.
4. Barbaccia M.L., Affricano D., Purdy R.H., Maciocco E., Spiga F., Biggio G. Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology. 25:2001;489-497.
5. Barbosa A.D., Morato G.S. Influence of neurosteroids on the development of rapid tolerance to ethanol in mice. Eur. J. Pharmacol. 431:2001;179-188.
6. Barrantes F.J., Antollini S.S., Bouzat C.B., Garbus I., Massol R.H. Nongenomic effects of steroids on the nicotinic acetylcholine receptor. Kidney Int. 57:2000;1382-1389.
7. Barrett-Connor E., von Muhlen D., Laughlin G.A., Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo study. J. Am. Geriatr. Soc. 47:1999;685-691.
8. Baulieu E.E. Neurosteroids: a new function in the brain. Biol. Cell. 71:1991;3-10.
9. Baulieu E.E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology. 23:1998;963-987.
10. Bäckström T., Zetterlund B., Blom S., Romano M. Effects of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy. Acta Neurol. Scand. 69:1984;240-248.
11. Beekman M., Ungard J.T., Gasior M., Carter R.B., Dijkstra D., Goldberg S.R., Witkin J.M. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. J. Pharmacol. Exp. Ther. 284:1998;868-877.
12. Belelli D., Lan N.C., Gee K.W. Anticonvulsant steroids and the GABA/benzodiazepine receptor-chloride ionophore complex. Neurosci. Biobehav. Rev. 14:1990;315-322.
13. Bernardi F., Lanzone A., Cento R.M., Spada R.S., Pezzani I., Genazzani A.D., Luisi S., Luisi M., Petraglia F., Genazzani A.R. Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia. Eur. J. Endocrinol. 142:2000;466-471.
14. Bicikova M., Dibbelt L., Hill M., Hampl R., Starka L. Allopregnanolone in women with premenstrual syndrome. Horm. Metab. Res. 30:1998;227-230.
15. Bicikova M., Tallová J., Hill M., Krausova Z., Hampl R. Serum concentrations of some neuroactive steroids in women suffering from mixed anxiety-depressive disorder. Neurochem. Res. 25:2000;1623-1627.
16. A receptor. Brain Res. 561:1991;157-161.
17. A receptors. J. Neuroendocrinol. 7:1995;171-177.
18. Browne E.S., Porter J.R., Correa G., Abadie J., Svec F. Dehydroepiandrosterone regulation of the hepatic glucocorticoid receptor in the Zucker rat. The obesity research program. J. Steroid Biochem. Mol. Biol. 45:1993;517-524.
19. Bullock A.E., Clark A.L., Grady S.R., Robinson S.F., Slobe B.S., Marks M.J., Collins A.C. Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes. J. Neurochem. 68:1997;2412-2423.
20. Carl P., Högskilde S., Nielsen J.W., Sörensen M.B., Lindholm M., Karlen B., Bäckström T. Pregnanolone emulsion: a preliminary pharmacokinetic and pharmacodynamic study of a new intravenous agent. Anaesthesia. 45:1990;189-197.
21. A receptor. J. Pharmacol. Exp. Ther. 280:1997;1284-1295.
22. Celotti F., Melcangi R.C., Martini L. The 5α-reductase in the brain: molecular aspects and relation to brain function. Front. Neuroendocrinol. 13:1992;163-215.
23. Chen R., Belelli D., Lambert J.J., Peters J.A., Reyes A., Lan N.C. Cloning and functional expression of a drosophila γ-aminobutyric acid receptor. Proc. Natl. Acad. Sci. USA. 91:1994;6069-6073.
24. Compagnone N.A., Mellon S.H. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front. Neuroendocrinol. 21:2000;1-56.
25. Concas A., Mostallino M.C., Porcu P., Follesa P., Barbaccia M.L., Trabucchi M., Purdy R.H., Grisenti P., Biggio G. Role of brain allopregnanolone in the plasticity of γ-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc. Natl. Acad. Sci. USA. 95:1998;13284-13289.
26. Crawley J.N., Glowa J.R., Majewska M.D., Paul S.M. Anxiolytic activity of an endogenous adrenal steroid. Brain Res. 398:1986;382-385.
27. Damianisch K., Rupprecht R., Lancel M. The influence of subchronic administration of the neurosteroid allopregnanolone on sleep in the rat. Neuropsychopharmacology. 25:2001;576-584.
28. 3B subunit is a major determinant of serotonin-receptor function. Nature. 397:1999;359-363.
29. Devaud L.L., Purdy R.H., Morrow A.L. The neurosteroid 3α-hydroxy-5α-pregnan-20-one, protects against bicuculline-induced seizures during ethanol withdrawal in rats. Alcohol. Clin. Exp. Res. 19:1995;350-355.
30. Dong E., Matsumoto K., Uzunova V., Sugaya I., Takahata H., Nomura H., Watanabe H., Costa E., Guidotti A. Brain 5α-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl. Acad. Sci. USA. 98:2001;2849-2854.
31. van Doren M.J., Matthews D.B., Janis G.C., Grobin A.C., Devaud L.L., Morrow A.L. Neuroactive steroid 3alpha-hydroxy-5alpha-pregnan-20-one modulates electrophysiological and behavioral actions of ethanol. J. Neurosci. 20:2000;1982-1989.
32. Edgar D.M., Seidel W.F., Gee K.W., Lan N.C., Field G., Xia H., Hawkinson J.E., Wieland S., Carter R.B., Wood P.L. CCD-3693: an orally bioavailable analog of the endogenous neuroactive steroid, pregnanolone, demonstrates potent sedative hypnotic actions in the rat. J. Pharmacol. Exp. Ther. 282:1997;420-429.
33. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
34. Fabian T.J., Dew M.A., Pollock B.G., Reynolds C.F., Mulsant B.H., Butters M.A., Zmuda M.D., Linares A.M., Trottini M., Kroboth P.D. Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults. Biol. Psychiatry. 50:2001;767-774.
35. Flood J.F., Morley J.E., Roberts E. Memory-enhancing effects in male mice of pregnenolone and of steroids metabolically derived from it. Proc. Natl. Acad. Sci. USA. 89:1992;1567-1571.
36. Flood J.F., Smith G.E., Roberts E. Dehydroepiandrosterone and its sulfate enhance memory retention in mice. Brain Res. 447:1988;269-278.
37. Friess, E., Tagaya, H., Trachsel, L., Holsboer, F., Rupprecht, R., 1997, Progesterone-induced changes in sleep in male subjects, Am. J. Physiol. 272, E885-E891.
38. A receptor complex modulate pain sensitivity in rats. Brain Res. 643:1994;194-203.
39. Frye C.A., Scalise T.J. Anti-seizure effects of progesterone and 3α, 5α-THP in kainic acid and perforant pathway models of epilepsy. Psychoneuroendocrinology. 25:2000;407-420.
40. Gasior M., Carter R.B., Goldber S.R., Witkin J.M. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjuction with diazepam. J. Pharmacol. Exp. Ther. 282:1997;543-553.
41. Gasior M., Carter R.B., Witkin J.M. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol. Sci. 20:1999;107-112.
42. Gee K.W., Bolger M.B., Brinton R.E., Coirini H., McEwen B.S. Steroid modulation of the chloride ionophore in rat brain: structure-activity requirements, regional dependance and mechanism of action. J. Pharmacol. Exp. Ther. 246:1988;803-812.
43. Girdler S.S., Straneva P.A., Light K.C., Pedersen C.A., Morrow A.L. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol. Psychiatry. 49:2001;788-797.
44. Grazzini E., Guillon G., Mouillac B., Zingg H.H. Inhibition of oxytocin receptor function by direct binding of progesterone. Nature. 392:1998;509-512.
45. Griffin L.D., Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA. 96:1999;13512-13517.
46. Grobin, A.C., Morrow, A.L., 2000, 3α-hydroxy-5α-pregnan-20-one exposure reduces GABA(A) receptor α4 subunit mRNA levels, Eur. J. Pharmacol., 409, R1-R2.
47. Gyermek L., Soyka L.F. Steroid anesthetics. Anesthesiology. 42:1975;116-121.
48. Halbreich U., Kahn L.S. Selective estrogen receptor modulators-current and future brain and behavior applications. Expert Opin. Pharmacother. 1:2000;1385-1398.
49. Hallonquist J.D., Seeman M.V., Lang M., Rector N.A. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol. Psychiatry. 33:1993;207-209.
50. Häfner H., Riecher-Rössler A., an der Heiden W., Maurer K., Fätkenheuer B., Löffler W. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychol. Med. 23:1993;925-940.
51. A) receptors in two Wistar rat lines selectively bred for high and low anxiety-related behaviour. World J. Biol. Psychiatry. 1:2000;137-143.
52. Herzog A.G. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology. 45:1995;1660-1662.
53. Heuser I., Deuschle M., Luppa P., Schweiger U., Standhardt H., Weber B. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J. Clin. Endocrinol. Metab. 83:1998;3130-3133.
54. Hillen T., Lun A., Reischies F.M., Borchelt M., Steinhagen-Thiessen E., Schaub R.T. DHEA-S plasma levels and incidence of Alzheimer's disease. Biol. Psychiatry. 47:2000;161-163.
55. Huppert, F.A., Niekerk, J.K., 2001, Dehydroepiandrosterone (DHEA) supplementation for cognitive function (Cochrane Review). Cochrane Database Syst. Rev., 2, CD000304.
56. Janis G.C., Devaud L.L., Mitsuyama H., Morrow A.L. Effects of chronic ethanol consumption and withdrawal on the neuroactive steroid 3α-hydroxy-5α-pregnan-20-one in male and female rats. Alcohol. Clin. Exp. Res. 22:1998;2055-2061.
57. Khisti R.T., Chopde C.T., Jain S.P. Antidepressant-like effect of the neurosteroid 3α-hydroxy-5α-pregnan-20-one in mice forced swim test. Pharmacol. Biochem. Behav. 67:2000;137-143.
58. Kliewer S.A., Moore J.T., Wade L., Staudinger J.L., Watson M.A., Jones S.A., McKee D.D., Oliver B.B., Willson T.M., Zetterström R.H., Perlmann T., Lehmann J.M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 92:1998;73-82.
59. Kokate T.G., Svensson B.E., Rogawski M.A. Anticonvulsant activity of neurosteroids: correlation with γ-aminobutyric acid-evoked chloride current potentiation. J. Pharmacol. Exp. Ther. 270:1994;1223-1229.
60. Korneyev A., Costa E. Allopregnanolone (THP) mediates anesthetic effects of progesterone in rats. Horm. Behav. 30:1996;37-43.
61. Korpi E.R., Makela R., Romeo E., Guidotti A., Uusi-Oukari M., Furnari C., di Michele F., Sarviharju M., Xu M., Rosenberg P.H. Increased behavioral neurosteroid sensitivity in a rat line selectively bred for high alcohol sensitivity. Eur. J. Pharmacol. 421:2001;31-38.
62. Kulkarni J., de Castella A., Smith D., Taffe J., Keks N., Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 20:1996;247-252.
63. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., Burger H. Estrogen - a potential treatment for schizophrenia. Schizophr. Res. 48:2001;137-144.
64. Ladurelle N., Eychenne B., Denton D., Blair-West J., Schumacher M., Robel P., Baulieu E. Prolonged intracerebroventricular infusion of neurosteroids affects cognitive performances in the mouse. Brain Res. 858:2000;371-379.
65. A receptor function. Trends Pharmacol. Sci. 16:1995;295-303.
66. A receptor modulators, Am. J. Physiol. 271, E763-E772.
67. A receptor antagonist picrotoxin attenuates most of the sleep changes induced by progesterone. Psychopharmacology. 141:1999;213-219.
68. Lancel M., Faulhaber J., Schiffelholz T., Romeo E., di Michele F., Holsboer F., Rupprecht R. Allopregnanolone affects sleep in a benzodiazepine-like fashion. J. Pharmacol. Exp. Ther. 282:1997;1213-1218.
69. Le Melledo J.-M., Merani S., Koszycki D., Bellavance F., Palmour R., Gutkowska J., Steinberg S., Bichet D.G., Bradwejn J. Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology. 20:1999;81-91.
70. Maayan R., Yagorowski Y., Grupper D., Weiss M., Shtaif B., Kaoud M.A., Weizman A. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biol. Psychiatry. 48:2000;693-701.
71. A receptor isoforms. Can. J. Physiol. Pharmacol. 76:1998;909-920.
72. A receptor function by neuroactive steroids. Brain Res. 819:1999;75-82.
73. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 232:1986;1004-1007.
74. 3 receptor, a serotonin-gated ion channel. Science. 254:1991;432-437.
75. Marx C.E., Duncan G.E., Gilmore J.H., Lieberman J.A., Morrow A.L. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol. Psychiatry. 47:2000;1000-1004.
76. McEwen B.S. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol. Sci. 12:1991;141-147.
77. Mellon S.H. Neurosteroids: biochemistry, modes of action and clinical relevance. J. Clin. Endocrinol. Metab. 78:1994;1003-1008.
78. Mendelson W.B., Martin J.V., Perlis M., Wagner R., Majewska M.D., Paul S.M. Sleep induction by an adrenal steroid in the rat. Psychopharmacology. 93:1987;226-229.
79. Molina-Hernández M., Téllez-Alcántara N.P. Antidepressant-like actions of pregnancy, and progesterone in Wistar rats forced to swim. Psychoneuroendocrinology. 26:2001;479-491.
80. Monaghan E.P., McAuley J.W., Data J.L. Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy. Expert Opin. Invest. Drugs. 8:1999;1663-1671.
81. Monaghan E.P., Navalta L.A., Shum L., Ashbrock D.W., Lee D.A. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia. 38:1997;1026-1031.
82. 3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc. Natl. Acad. Sci. USA. 92:1995;3774-3778.
83. Monteleone P., Luisi S., Tonetti A., Bernardi F., Genazzani A.D., Luisi M., Petraglia F., Genazzani A.R. Allopregnanlone concentrations and premenstrual syndrome, Eur. J. Endocrinol. 142:2000;269-273.
84. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Willson T.M., Collins J.L., Kliewer S.A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA. 97:2000;7500-7502.
85. Murialdo G., Barreca A., Nobili F., Rollero A., Timossi G., Gianelli M.V., Copello F., Rodriguez G., Polleri A. Relationships between cortisol, dehydroepiansrosterone sulphate and insulin-like growth factor-1 system in dementia. J. Endocrinol. Invest. 24:2001;139-146.
86. Nadeson R., Goodchild C.S. Antinociceptive properties of neurosteroids III: experiments with alphadolone given intravenously, intraperitoneally, and intragastrically. Br. J. Anaesth. 86:2001;704-708.
87. Näsman B., Olsson B., Bäckström T., Eriksson S., Grankvist K., Viitanen M., Bucht G. Serum dehydroepiandrosterone sulfate in Alzheimer's disease and in multiinfarct dementia. Biol. Psychiatry. 30:1991;684-690.
88. van Niekerk J.K., Huppert F.A., Herbert J. Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology. 26:2001;591-612.
89. Orchinik M., Murray T.F., Moore F.L. A corticosteroid receptor in neuronal membranes. Science. 252:1991;1848-1851.
90. Pappas T.D., Gametchu B., Watson C.S. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 9:1995;404-410.
91. Park-Chung M., Wu F.S., Farb D.H. 3α-hydroxy -5beta-pregnan-20-one sulfate: a negative modulator of the NMDA-induced current in cultured neurons. Mol. Pharmacol. 46:1994;146-150.
92. Patchev V.K., Montkowski A., Rouskova D., Koranyi L., Holsboer F., Almeida O.F.X. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neurondocrine consequences of adverse early life events. J. Clin. Invest. 99:1997;962-966.
93. Patchev V.K., Shoaib M., Holsboer F., Almeida O.F.X. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience. 62:1994;265-271.
94. Paul S.M., Purdy R.H. Neuroactive steroids. FASEB J. 6:1992;2311-2322.
95. Pearson Murphy B.E., Steinberg S.I., Hu F.-Y., Allison C.M. Neuroactive ring A-reduced metabolites of progesterone in human plasma during pregnancy: elevated levels of 5alpha-dihydroprogesterone in depressed patients during the latter half of pregnancy. J. Clin. Endocrinol. Metab. 86:2001;5981-5987.
96. A receptor-complex. Neurosci. Lett. 135:1992;273-275.
97. A receptors. Neuron. 4:1990;759-765.
98. Ramirez V.D., Zheng J. Membrane sex-steroid receptors in the brain. Front. Neuroendocrinol. 17:1996;402-439.
99. Rapkin A.J., Morgan M., Goldman L., Brann D.W., Simone D., Mahesh V.B. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol. 90:1997;709-714.
100. Rasgon N., Serra M., Biggio G., Pisu M.G., Fairbanks L., Tanavoli S., Rapkin A. Neuroactive steroid-serotonergic interaction: responses to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Eur. J. Endocrinol. 145:2001;25-33.
101. Reddy D.S., Rogawski M.A. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol. Exp. Ther. 295:2000;1241-1248.
102. Rick C.E., Ye Q., Finn S.E., Harrison N.L. Neurosteroids act on the GABA(A) receptor at sites on the N-terminal side of the middle of TM2. Neuroreport. 9:1998;379-383.
103. Romeo E., Brancati A., De Lorenzo A., Fucci P., Furnari C., Pompili E., Sasso G.F., Spalletta G., Troisi A., Pasini A. Marked decrease of plasma neuroactive steroids during alcohol withdrawal. Clin. Neuropharmacol. 19:1996;366-369.
104. Romeo E., Pompili E., di Michele F., Pace M., Rupprecht R., Bernardi G., Pasini A. Effects of fluoxetine, indomethacine and placebo on 3α, 5α tetrahydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal. World J. Biol. Psychiatry. 1:2000;101-104.
105. Romeo E., Ströhle A., Spalletta G., di Michele F., Hermann B., Holsboer F., Pasini A., Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry. 155:1998;910-913.
106. Rupprecht R. The neuropsychopharmacological potential of neuroactive steroids. J. Psychiatr. Res. 31:1997;297-314.
107. Rupprecht R., Berning B., Hauser C.A.E., Holsboer F., Reul J.M.H.M. Steroid receptor mediated effects of neuroactive steroids: characterization of structure-activity relationship. Eur. J. Pharmacol. 303:1996;227-234.
108. Rupprecht R., Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 22:1999;410-416.
109. Rupprecht R., Koch M., Montkowski A., Lancel M., Faulhaber J., Harting J., Spanagel R. Assessment of neuroleptic-like properties of progesterone. Psychopharmacology. 143:1999;29-38.
110. Rupprecht R., Reul J.M.H.M., Trapp T., van Steensel B., Wetzel C., Damm K., Zieglgänsberger W., Holsboer F. Progesterone receptor-mediated effects of neuroactive steroids. Neuron. 11:1993;523-530.
111. Schulz H., Jobert M., Gee K.W., Ashbrook D.W. Soporific effect of the neurosteroid pregnanolone in relation to the substance's plasma level: a pilot study. Neuropsychobiology. 34:1996;106-112.
112. Serra M., Littera M., Pisu M.G., Muggironi M., Purdy R.H., Biggio G. Steroidogenesis in rat brain induced by short- and long-term administration of carbamazepine. Neuropharmacology. 39:2000;2448-2456.
113. Serra M., Pisu M.G., Muggironi M., Parodo V., Papi G., Sari R., Dazzi L., Spiga F., Purdy R.H., Biggio G. Opposite effects of short- versus long-term administration of fluoxetine on the concentrations of neuroactive steroids in rat plasma and brain. Psychopharmacology. 158:2001;48-54.
114. A receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature. 392:1998;926-930.
115. A receptor alpha4 subunit in association with increased anxiety. J. Neurosci. 18:1998;5275-5284.
116. Sooksawate T., Simmonds M.A. Influence of membrane cholesterol on modulation of the GABA(A) receptor by neuroactive steroids and other potentiators. Br. J. Pharmacol. 134:2001;1303-1311.
117. Steiner M., Steinberg S., Stewart D., Carter D., Berger C., Reid R., Grover D., Streiner D. Fluoxetine in the treatment of premenstrual dysphoria. N. Engl. J. Med. 332:1995;1529-1534.
118. Ströhle A., Pasini A., Romeo E., Hermann B., Spalletta G., di Michele F., Holsboer F., Rupprecht R. Fluoxetine decreases concentrations of 3α, 5α-tetrahydrodeoxycorticosterone (THDOC) in major depression. J. Psychiatr. Res. 34:2000;183-186.
119. A receptor modulatory steroid composition in patients with panic disorder: Preliminary results. Arch. Gen. Psychiatry, in press.
120. A receptor modulatory neuroactive steroid composition in panic disoder and during paroxetine treatment. Am. J. Psychiatry. 159:2002;145-147.
121. Ströhle A., Romeo E., Hermann B., Pasini A., Spalletta G., di Michele F., Holsboer F., Rupprecht R. Concentrations of 3α-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol. Psychiatry. 45:1999;247-277.
122. Strous R.D., Spivak B., Yoran-Hegesh R., Maayan R., Averbuch E., Kotler M., Mester R., Weizman A. Analysis of neurosteroid levels in attention deficit hyperactivity disorder. Int. J. Neuropsychoparmacol. 4:2001;259-264.
123. Su T.-P., London E.D., Jaffe J.H. Steroid binding at σ receptors suggests a link between endocrine, nervous, and immune systems. Science. 240:1988;219-221.
124. Sunderland T., Merril C.R., Harrington M.G., Lawlor B.A., Molchan S.E., Martinez R., Murphy D.L. Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disesase. Lancet. II:1989;570-572.
125. Sundström I., Bäckström T. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology. 23:1998;73-88.
126. Tecott L.H., Julius D. A new wave of serotonin receptors. Curr. Opin. Neurobiol. 3:1993;310-315.
127. Thomas G., Frenoy N., Legrain S., Sebag-Lanoe R., Baulieu E.E., Debuire B. Serum dehydroepiandrosterone sulfate levels as an individual marker. J. Clin. Endocrinol. Metab. 79:1994;1273-1276.
128. Truss M., Beato M. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocrine Rev. 14:1993;459-479.
129. Uzunov D.P., Cooper T.B., Costa E., Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sci. USA. 93:1996;12599-12604.
130. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. USA. 95:1998;3239-3244.
131. Valera S., Ballivet M., Bertrand D. Progesterone modulates a neuronal nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. USA. 89:1992;9949-9953.
132. Vallee M., Mayo W., Darnaudery M., Corpechot C., Young J., Koehl M., Le Moal M., Baulieu E.E., Robel P., Simon H. Neurosteroids: deficient cognitive performance in aged rats depends on low pregnenolone sulfate levels in the hippocampus. Proc. Natl. Acad. Sci. USA. 94:1997;14865-14870.
133. A receptors. J. Pharmacol. Exp. Ther. 295:2000;337-345.
134. Weaver C.E. Jr., Marek P., Park-Chung M., Tam S.W., Farb D.H. Neuroprotective activity of a new class of steroidal inhibitors of the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. USA. 94:1997;10450-10454.
135. Weaver C.E. Jr., Park-Chung M., Gibbs T.T., Farb D.H. 17β-estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res. 761:1997;338-341.
136. Wehling M. Specific, nongenomic actions of steroid hormones. Annu. Rev. Physiol. 59:1997;365-393.
137. 3 receptor. Mol. Endocrinol. 12:1998;1441-1451.
138. Wieland S., Lan N.C., Mirasedeghi S., Gee K.W. Anxiolytic activity of the progesterone metabolite 5α-pregnan-3α-ol-20-one. Brain Res. 565:1991;263-268.
139. Wolf O.T., Kudielka B.M., Hellhammer D.H., Hellhammer J., Kirschbaum C. Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressor. Psychoneuroendocrinology. 23:1998;617-629.
140. Wolkowitz O.M., Reus V.I., Keebler A., Nelson N., Friedland M., Brizendine L., Roberts E. Double-blind treatment of major depression with dehydroepiandrosterone. Am. J. Psychiatry. 156:1999;646-649.
141. Wolkowitz O.M., Reus V.I., Roberts E., Manfredi F., Chan T., Raum W.J., Ormiston S., Johnson R., Canick J., Brizendine L., Weingartner H. Dehydroepiandrosterone (DHEA) treatment of depression. Biol. Psychiatry. 41:1997;311-318.
142. Wu F.-S., Gibbs T.T., Farb D.H. Inverse modulation of γ-aminobutyric acid- and glycine-induced currents by progesterone. Mol. Pharmacol. 37:1990;597-602.
143. Wu F.-S., Gibbs T.T., Farb D.H. Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor. Mol. Pharmacol. 40:1991;333-336.
144. Zakon H.H. The effects of steroid hormones on electrical activity of excitable cells. Trends Neurosci. 21:1998;202-207.
145. Zorumski C.F., Mennerick S., Isenberg K.E., Covey D.F. Potential clinical uses of neuroactive steroids. Curr. Opin. Invest. Drugs. 1:2000;360-369.